Completed PHASE4 INTERVENTIONAL 1-arm NCT00381381

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

Sponsor: Eisai Korea Inc.

Conditions Alzheimer's Disease

Interventions Donepezil

Updated 7 times since 2017 Last updated: Dec 10, 2021 Started: May 31, 2006 Primary completion: Aug 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Alzheimer's Disease and is currently completed. Eisai Korea Inc. leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jan 2022 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Korea Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bundang, South Korea , Changwon, South Korea , Chuncheon, South Korea , Chungju, South Korea , Daegu, South Korea , Daejeon, South Korea , Gyeonggi-do, South Korea , Jeju City, South Korea , Jeonju, South Korea , Jinju, South Korea and 2 more locations